FDA Approves Shield Therapeutics’ AccruFeR for Pediatric Use

The expanded labeling targets a demographic where iron deficiency remains a persistent clinical challenge. According to Shield Therapeutics, approximately 2.4 million children in the United States suffer from the condition, with adolescents identified as a particularly high-risk group. This regulatory milestone allows the company to transition its flagship product into the pediatric market, addressing a gap in available prescription oral therapies.

Clinical Advantages of Non-Salt Therapy

AccruFeR distinguishes itself from traditional treatments through its chemical composition. Unlike conventional oral iron supplements that typically rely on iron salts, this therapy is a stable, non-salt-based formulation. The company states that its novel absorption mechanism allows the drug to be effectively processed by the body, which has historically been a hurdle for patients sensitive to standard iron salts.

Data from clinical trials indicates that the treatment is well-tolerated among younger patients. By providing a non-salt alternative, the company aims to offer a more manageable prescription option for clinicians treating chronic deficiency in minors aged 10 and older. This approval marks the first major regulatory expansion for the product since it entered the U.S. market in 2019.